Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-05-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
浙江天册律师事务所关于公司2018年（第二期）股票期权激励计划第一次行权等相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2018 (second phase) stock option incentive plan of Betta Pharmaceuticals Co., Ltd. It details the legal review and confirmation of the stock option plan's approval, authorization, price adjustment, partial cancellation, and the first exercise of stock options. The document includes references to relevant laws, company board and shareholder meetings, and compliance with regulatory requirements. It is not a financial report, earnings release, or management discussion, but a legal opinion on stock option incentive plan matters. This type of document fits best under Regulatory Filings (RNS) as it is a legal opinion letter related to corporate governance and compliance, not a direct financial or management report or announcement of voting results or capital changes.
2020-05-22 Chinese
第三届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It details the convening of the third board's sixth meeting, voting results on various proposals related to stock option plans, and other corporate governance matters. The text includes specifics about meeting attendance, voting outcomes, and references to related disclosures on the official stock exchange information website. There are no financial statements or detailed financial performance data presented. The document is primarily about board decisions and management-level corporate governance actions, specifically about stock option adjustments and approvals. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 3427 characters, which is consistent with a meeting resolution announcement rather than a full report or regulatory filing. Hence, the classification is MANG with high confidence.
2020-05-22 Chinese
浙江天册律师事务所关于公司2018年（第一期）股票期权激励计划第二次行权等相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2018 stock option incentive plan of Betta Pharmaceuticals Co., Ltd. It details the legal review and confirmation of the stock option plan's approval, authorization, price adjustments, cancellations, and the second exercise of stock options. The document references specific board meetings, shareholder meetings, and compliance with relevant laws and regulations. It is not a financial report, earnings release, or regulatory announcement but a specialized legal opinion on stock option incentive plan matters. This type of document fits best under the category of Regulatory Filings (RNS) as it is a legal opinion letter related to corporate governance and compliance rather than a direct financial or management report.
2020-05-22 Chinese
2018年（第二期）股票期权激励计划首次授予期权第一个行权期可行权激励对象名单
Board/Management Information Classification · 95% confidence The document is titled as the "2018 Year (Second Phase) Stock Option Incentive Plan First Grant Option" and lists detailed information about the stock options granted to directors, senior management, and other key personnel. It includes names, positions, and quantities of stock options exercisable. This type of document is related to management and board-level information, specifically about stock option grants to executives and key employees. It is not a full annual report, earnings release, or regulatory filing about financial results. It is also not a voting result, dividend notice, or capital change announcement. The content focuses on management stock option incentives, which falls under announcements related to board/management information. Therefore, the most appropriate classification is "Board/Management Information (MANG)". The document length is about 4945 characters, which is sufficient to contain substantive information rather than a brief announcement or certification. Confidence is high given the clear focus on management stock option grants.
2020-05-22 Chinese
关于2018年（第二期）股票期权激励计划首次授予股票期权第一个行权期可行权的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the first exercise period of the 2018 (second phase) stock option incentive plan by Betta Pharmaceuticals Co., Ltd. It details the approval process, adjustments to the stock options, exercise conditions, and the list of eligible participants. It includes information on the stock option plan, exercise price adjustments, and legal and supervisory opinions. The document is not a full financial report, earnings release, or management discussion but rather a formal announcement about stock option exercises and related corporate governance matters. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about stock option exercises and related approvals, not a full report or financial statement.
2020-05-22 Chinese
独立董事关于第三届董事会第六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the company's third board of directors' sixth meeting. It includes detailed opinions on stock option incentive plans, adjustments, cancellations, and the establishment of a securities investment management system. The content focuses on governance and compliance with regulations related to stock option plans and internal company policies. There is no financial data, earnings information, or report publication announcement. The document is a formal opinion related to board meeting decisions and governance matters, specifically about stock option plans and internal controls. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management, including governance-related opinions and approvals.
2020-05-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.